Friday - August 15, 2025
HKUMed Leads Global Drug Development Using New 'Dual Immunotherapy' in Liver-cancer Patients, Improving Survival Benefits; Receives International Approvals
June 21, 2025
HONG KONG, June 21 (TNSjou) -- The University of Hong Kong issued the following news release:

* * *

HKUMed leads global drug development using new 'dual immunotherapy' in liver-cancer patients, improving survival benefits; receives international approvals

A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has pioneered the use of a 'dual immunotherapy' combination-- . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products